A Beta-only IL-2 ImmunoTherapY Study (NCT05086692)
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.
Who can join: Review the eligibility criteria below.
Location: Sharp Memorial Hospital — San Diego, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- Sharp Memorial Hospital — San Diego, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Providence Saint John's Health Center — Santa Monica, California
- Boca Raton Regional Hospital — Boca Raton, Florida
- Emory - Winship Cancer Institute — Atlanta, Georgia
- Karmanos Cancer Institute — Detroit, Michigan
- MD Anderson Cancer Center — Houston, Texas
- Scientia Clinical Research — Randwick, New South Wales
- Macquarie University — Sydney, New South Wales
- University of the Sunshine Coast — Buderim, Queensland
- Gallipoli Medical Research Foundation — Greenslopes, Queensland
- Princess Margaret Cancer Center — Toronto, Ontario
- Mater Misericordiae University Hospital — Dublin,
- START Lisbon - Centro de Ensaios Clínicos, ULS Sta Maria — Lisbon,
- Instituto Portugues De Oncologia Do Porto — Porto,
- Samsung Medical Center — Seoul, Gangnam-gu
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do
- The Catholic University of Korea St. Vincent Hospital — Suwon, Gyeonggi-do
- Seoul National University Hospital — Seoul, Jongno-gu
- Institut Catala d'Oncologia (ICO)-Badalona — Badalona,
- START Barcelona / HM Nou Delfos — Barcelona,
- Hospital de la Santa Creu i Sant Pau — Barcelona,
- Hospital Universitario Ramón y Cajal — Madrid,
- START Madrid / Hospital Universitario Fundacion Jimenez Diaz — Madrid,
- Hospital Universitario Hm Sanchinarro — Madrid,
📞 Contact the Study Coordinator
Phone: (604) 340-3081
Email: nmerchant@medicenna.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Solid Tumor
- Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression — Iowa City, Iowa
- A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors — Glendale, California
- QTX3046 in Patients With KRAS G12D Mutations — Grand Rapids, Michigan
- A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors — Houston, Texas
- First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer — Fullerton, California
- A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors — San Antonio, Texas
Explore by condition: All Advanced Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.